The Ongoing Debate Over Peptides: Regulatory Challenges and Consumer Confusion

Recent attention has focused on peptides, which are gaining popularity as experimental drugs. In July, a panel advising the Food and Drug Administration (FDA) conducted a lengthy hearing concerning peptides. The panel debated the approval of seven different peptide therapies, ultimately recommending all but one, despite reservations from FDA scientists.

These peptides, including popular ones like BPC-157, TB-500, and MOTS-c, remain illegal for US pharmacies to produce. The FDA must now assess the data before deciding if compounding pharmacies can manufacture any of these. Dr. Jessica Duncan from IVIM Health highlighted the rising curiosity among consumers about these therapies’ availability, but the timeline remains unclear.

Prospects of Peptide Approval

While FDA approval isn’t guaranteed, the agency often aligns with its advisory committees. With significant demand and support from Health Secretary Robert F. Kennedy Jr., the FDA might expedite the process. Legal expert Jesse Dresser notes that the usual rulemaking process could take many months or even over a year. However, alternative pathways could expedite approval.

A likely route involves adding these peptides to the “Category One list.” This would allow pharmacies to begin production as the rulemaking process continues. Former FDA official Ilisa Bernstein stresses the need for FDA to follow the data carefully.

Another potential route could involve immediate authorization due to the risks posed by the unregulated peptide market. Yet, this approach usually applies to removing unsafe products, not accelerating approval, explains Dresser.

If the FDA disregards the panel’s recommendations, industry lawsuits may follow. Attorney Abha Kundi emphasizes the agency’s awareness of the market dynamics. “In many ways,” Kundi notes, “the toothpaste is out of the tube.”

Why Peptides Are Controversial

Interest in peptides surged ahead of scientific evidence. Commonly promoted in wellness spaces, they are used for recovery, muscle growth, and fat loss. Unlike FDA-approved drugs, these peptides lack rigorous human trials. The gray market for peptides has grown, mainly due to previous FDA restrictions on their compounding.

Dr. Haleem Mohammed, an FDA panelist and supporter of peptides, expressed concerns about where people obtain these substances. He argues the discussion lacked comprehensive evidence. “This is about moving towards a regulated pathway for peptides,” he said, advocating for a safer market.

FDA scientists highlighted insufficient human data and challenges in defining the peptides due to variations in their chemical makeup. Although compounding approval requires less evidence than drug approval, safety assurances are still necessary. Bernstein notes the significant market impact should the FDA support peptides.

How Consumers Might Access Peptides

If approved, peptides will need prescriptions but won’t be available at typical pharmacies like CVS or Walgreens. They will be prepared by compounding pharmacies, which will take time to source ingredients. Scott Brunner from the Alliance for Pharmacy Compounding predicts it may take months to ramp up production.

Telehealth companies and med spas already promote peptides, but conventional doctors remain cautious. Although training is available for peptide medicine, there are no comprehensive, evidence-based guidelines from major medical bodies.

Dr. Harmeet Narula cautions that commercial enthusiasm outstrips clinical evidence. He emphasizes that recent developments do not equate to FDA approval.